SEC Comment Letter for Transcode Therapeutics, (RNAZ) — May 6, 2026
Transcode Therapeutics, Inc.
Date: May 6, 2026 · CIK: 0001829635 · Accession: 0000000000-26-004640
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295481
Letter
Re: TransCode Therapeutics, Inc. Registration Statement on Form S-1 Filed May 1, 2026 File No. 333-295481 Dear Philippe P. Calais:
May 6, 2026
Philippe P. Calais Chief Executive Officer TransCode Therapeutics, Inc. 6 Liberty Square, #2382 Boston, MA 02109
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Niki Fang, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> May 6, 2026 Philippe P. Calais Chief Executive Officer TransCode Therapeutics, Inc. 6 Liberty Square, #2382 Boston, MA 02109 Re: TransCode Therapeutics, Inc. Registration Statement on Form S-1 Filed May 1, 2026 File No. 333-295481 Dear Philippe P. Calais: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Niki Fang, Esq. </TEXT> </DOCUMENT>